Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more
Market Cap & Net Worth: Harbin Medisan Pharmaceutical Co Ltd (002900)
Harbin Medisan Pharmaceutical Co Ltd (SHE:002900) has a market capitalization of $517.40 Million (CN¥3.80 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #16012 globally and #4272 in its home market, demonstrating a 0.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harbin Medisan Pharmaceutical Co Ltd's stock price CN¥12.00 by its total outstanding shares 316354550 (316.35 Million).
Harbin Medisan Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Harbin Medisan Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows change from $712.93 Million to $517.40 Million (-2.60% CAGR).
Harbin Medisan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harbin Medisan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.38x
Harbin Medisan Pharmaceutical Co Ltd's market cap is 0.38 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
7.24x
Harbin Medisan Pharmaceutical Co Ltd's market cap is 7.24 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $712.93 Million | $1.15 Billion | $181.08 Million | 0.62x | 3.94x |
| 2018 | $457.13 Million | $2.17 Billion | $205.81 Million | 0.21x | 2.22x |
| 2019 | $475.07 Million | $2.10 Billion | $177.18 Million | 0.23x | 2.68x |
| 2020 | $377.19 Million | $1.34 Billion | $29.32 Million | 0.28x | 12.86x |
| 2021 | $851.53 Million | $945.80 Million | $350.95 Million | 0.90x | 2.43x |
| 2022 | $572.36 Million | $1.03 Billion | $30.21 Million | 0.56x | 18.95x |
| 2023 | $576.80 Million | $1.19 Billion | $73.66 Million | 0.49x | 7.83x |
| 2024 | $424.70 Million | $1.13 Billion | $58.68 Million | 0.38x | 7.24x |
Competitor Companies of 002900 by Market Capitalization
Companies near Harbin Medisan Pharmaceutical Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Harbin Medisan Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Harbin Medisan Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Harbin Medisan Pharmaceutical Co Ltd's market cap moved from $712.93 Million to $ 517.40 Million, with a yearly change of -2.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥517.40 Million | -3.69% |
| 2025 | CN¥537.23 Million | +26.50% |
| 2024 | CN¥424.70 Million | -26.37% |
| 2023 | CN¥576.80 Million | +0.78% |
| 2022 | CN¥572.36 Million | -32.78% |
| 2021 | CN¥851.53 Million | +125.76% |
| 2020 | CN¥377.19 Million | -20.60% |
| 2019 | CN¥475.07 Million | +3.92% |
| 2018 | CN¥457.13 Million | -35.88% |
| 2017 | CN¥712.93 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Harbin Medisan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $517.40 Million USD |
| MoneyControl | $517.40 Million USD |
| MarketWatch | $517.40 Million USD |
| marketcap.company | $517.40 Million USD |
| Reuters | $517.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.